| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc. | Rusfertide - (VERIFY) | Polycythemia vera | NDA Filing | Ongoing | Subcutaneous | Hematology |
| Protagonist Therapeutics Inc. | Rusfertide - (VERIFY) | Polycythemia vera | NDA Filing | Ongoing | Subcutaneous | Hematology |
| Protagonist Therapeutics Inc. | Icotrokinra (JNJ-2113) - (ICONIC-TOTAL) | Moderate-to-severe psoriasis | NDA Filing | Data Released | Oral | Immunology: Anti-TNF |
| Protagonist Therapeutics Inc. | Icotrokinra (JNJ-2113) - (ICONIC-LEAD) | Moderate-to-severe psoriasis | Phase 3 | Data Released | Oral | Immunology: Anti-TNF |
| Protagonist Therapeutics Inc. | JNJ-2113 - (ICONIC-ADVANCE 2) | Moderate-to-severe psoriasis | Phase 3 | Ongoing | Oral | Immunology: Anti-TNF |
| Protagonist Therapeutics Inc. | JNJ-2113 - (ICONIC-ADVANCE 1) | Moderate-to-severe psoriasis | Phase 3 | Ongoing | Oral | Immunology: Anti-TNF |
| Protagonist Therapeutics Inc. | Icotrokinra | Psoriatic Arthritis | Phase 3 | Trial Planned | Subcutaneous | Immunology: Anti-TNF |
| Protagonist Therapeutics Inc. | Icotrokinra (JNJ-2113) - (ANTHEM-UC) | Ulcerative colitis | Phase 2b | Data Released | Oral | Gastroenterology |